Astrazeneca (AZN) Operating Expenses (2009 - 2026)
Astrazeneca (AZN) posted quarterly Operating Expenses of $9.7 billion for Q2 2026, up 15.36% year-over-year from $8.4 billion in Q2 2025, and up 215.36% quarter-over-quarter from -$8.4 billion in Q1 2026.
Astrazeneca (AZN) Operating Expenses (2009 - 2026) Analysis & Trends
Astrazeneca's Operating Expenses history runs 18 years deep, the most recent figure standing at $9.7 billion for Q2 2026.
- In Q2 2026, Operating Expenses rose 15.36% year-over-year to $9.7 billion; the TTM figure through Jun 2026 stood at -$16.8 billion (up 4.4% YoY), while the FY2025 annual figure was $34.2 billion, up 1.8% from the prior year.
- Operating Expenses for Q2 2026 stood at $9.7 billion, up from -$8.4 billion in the prior quarter.
- The five-year high for Operating Expenses was $9.7 billion in Q2 2026, with the low at -$10.1 billion in Q4 2024.
- The 5-year median for Operating Expenses is -$7.5 billion (2023), against an average of -$6.0 billion.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses slumped 93.53% in 2022, then soared 205.98% in 2025.
- Astrazeneca's Operating Expenses stood at -$7.2 billion in 2022, then slipped by 16.53% to -$8.4 billion in 2023, then fell by 19.46% to -$10.1 billion in 2024, then increased by 7.27% to -$9.4 billion in 2025, then soared by 203.74% to $9.7 billion in 2026.
- Business Quant data shows AZN's Operating Expenses at $9.7 billion in Q2 2026, -$8.4 billion in Q1 2026, and -$9.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -5.98 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.70 Bn |
| Mar 31, 2026 | -8.41 Bn |
| Dec 31, 2025 | -9.35 Bn |
| Sep 30, 2025 | -8.75 Bn |
| Jun 30, 2025 | 8.41 Bn |
| Mar 31, 2025 | -7.65 Bn |
| Dec 31, 2024 | -10.09 Bn |
| Sep 30, 2024 | -8.26 Bn |
| Jun 30, 2024 | -7.94 Bn |
| Mar 31, 2024 | -7.28 Bn |
| Dec 31, 2023 | -8.44 Bn |
| Sep 30, 2023 | -7.38 Bn |
| Jun 30, 2023 | -7.65 Bn |
| Mar 31, 2023 | -6.67 Bn |
| Dec 31, 2022 | -7.25 Bn |
| Sep 30, 2022 | -6.74 Bn |
| Jun 30, 2022 | -7.23 Bn |
| Mar 31, 2022 | -7.10 Bn |
| Dec 31, 2021 | -7.70 Bn |
| Sep 30, 2021 | -7.70 Bn |